Literature DB >> 15831474

Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.

Dirk-E Schmidt-Arras1, Annette Böhmer, Boyka Markova, Chunaram Choudhary, Hubert Serve, Frank-D Böhmer.   

Abstract

Constitutive activation of receptor tyrosine kinases (RTKs) is a frequent event in human cancer cells. Activating mutations in Fms-like tyrosine kinase 3 (FLT-3), notably, internal tandem duplications in the juxtamembrane domain (FLT-3 ITD), have been causally linked to acute myeloid leukemia. As we describe here, FLT-3 ITD exists predominantly in an immature, underglycosylated 130-kDa form, whereas wild-type FLT-3 is expressed predominantly as a mature, complex glycosylated 150-kDa molecule. Endogenous FLT-3 ITD, but little wild-type FLT-3, is detectable in the endoplasmic reticulum (ER) compartment. Conversely, cell surface expression of FLT-3 ITD is less efficient than that of wild-type FLT-3. Inhibition of FLT-3 ITD kinase by small molecules, inactivating point mutations, or coexpression with the protein-tyrosine phosphatases (PTPs) SHP-1, PTP1B, and PTP-PEST but not RPTPalpha promotes complex glycosylation and surface localization. However, PTP coexpression has no effect on the maturation of a surface glycoprotein of vesicular stomatitis virus. The maturation of wild-type FLT-3 is impaired by general PTP inhibition or by suppression of endogenous PTP1B. Enhanced complex formation of FLT-3 ITD with the ER-resident chaperone calnexin indicates that its retention in the ER is related to inefficient folding. The regulation of RTK maturation by tyrosine phosphorylation was observed with other RTKs as well, defines a possible role for ER-resident PTPs, and may be related to the altered signaling quality of constitutively active, transforming RTK mutants.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831474      PMCID: PMC1084288          DOI: 10.1128/MCB.25.9.3690-3703.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  45 in total

Review 1.  Autoinhibitory mechanisms in receptor tyrosine kinases.

Authors:  Stevan R Hubbard
Journal:  Front Biosci       Date:  2002-02-01

Review 2.  Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

3.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

4.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

Review 5.  Intracellular functions of N-linked glycans.

Authors:  A Helenius; M Aebi
Journal:  Science       Date:  2001-03-23       Impact factor: 47.728

6.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Authors:  Mark Levis; Jeffrey Allebach; Kam-Fai Tse; Rui Zheng; Brenda R Baldwin; B Douglas Smith; Susan Jones-Bolin; Bruce Ruggeri; Craig Dionne; Donald Small
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

7.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Authors:  Ellen Weisberg; Christina Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

8.  Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.

Authors:  Y Minami; H Kiyoi; Y Yamamoto; K Yamamoto; R Ueda; H Saito; T Naoe
Journal:  Leukemia       Date:  2002-08       Impact factor: 11.528

9.  SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.

Authors:  Kevin W H Yee; Anne Marie O'Farrell; Beverly D Smolich; Julie M Cherrington; Gerald McMahon; Cecily L Wait; Laura S McGreevey; Diana J Griffith; Michael C Heinrich
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

10.  Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1.

Authors:  H Keilhack; M Müller; S A Böhmer; C Frank; K M Weidner; W Birchmeier; T Ligensa; A Berndt; H Kosmehl; B Günther; T Müller; C Birchmeier; F D Böhmer
Journal:  J Cell Biol       Date:  2001-01-22       Impact factor: 10.539

View more
  54 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

2.  Common and specific effects of TIE2 mutations causing venous malformations.

Authors:  Marjut Nätynki; Jaakko Kangas; Ilkka Miinalainen; Raija Sormunen; Riikka Pietilä; Julie Soblet; Laurence M Boon; Miikka Vikkula; Nisha Limaye; Lauri Eklund
Journal:  Hum Mol Genet       Date:  2015-08-28       Impact factor: 6.150

Review 3.  Effects of membrane trafficking on signaling by receptor tyrosine kinases.

Authors:  Marta Miaczynska
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-11-01       Impact factor: 10.005

4.  Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.

Authors:  Anne Kresinsky; Reinhard Bauer; Tina M Schnöder; Tobias Berg; Daria Meyer; Volker Ast; Rainer König; Hubert Serve; Florian H Heidel; Frank-D Böhmer; Jörg P Müller
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

5.  Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.

Authors:  Changsheng Guo; Catherine R Degnin; Melanie B Laederich; Gregory P Lunstrum; Paul Holden; Jeanie Bihlmaier; Deborah Krakow; Yoon-Jae Cho; William A Horton
Journal:  Cell Signal       Date:  2008-04-10       Impact factor: 4.315

6.  Differential regulation of FGFR3 by PTPN1 and PTPN2.

Authors:  Jonathan R St-Germain; Paul Taylor; Wen Zhang; Zhihua Li; Troy Ketela; Jason Moffat; Benjamin G Neel; Suzanne Trudel; Michael F Moran
Journal:  Proteomics       Date:  2014-12-17       Impact factor: 3.984

7.  UBC9-dependent association between calnexin and protein tyrosine phosphatase 1B (PTP1B) at the endoplasmic reticulum.

Authors:  Dukgyu Lee; Allison Kraus; Daniel Prins; Jody Groenendyk; Isabelle Aubry; Wen-Xin Liu; Hao-Dong Li; Olivier Julien; Nicolas Touret; Brian D Sykes; Michel L Tremblay; Marek Michalak
Journal:  J Biol Chem       Date:  2015-01-13       Impact factor: 5.157

8.  Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase.

Authors:  Veena Sangwan; Grigorios N Paliouras; Jasmine V Abella; Nadia Dubé; Anie Monast; Michel L Tremblay; Morag Park
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

9.  Efficient production of bioactive recombinant human Flt3 ligand in E. coli.

Authors:  Kenneth Verstraete; Sina Koch; Sevgi Ertugrul; Isabel Vandenberghe; Maarten Aerts; Gonzalez Vandriessche; Christian Thiede; Savvas N Savvides
Journal:  Protein J       Date:  2009-02       Impact factor: 2.371

10.  Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations.

Authors:  Nisha Limaye; Vinciane Wouters; Melanie Uebelhoer; Marjut Tuominen; Riikka Wirkkala; John B Mulliken; Lauri Eklund; Laurence M Boon; Miikka Vikkula
Journal:  Nat Genet       Date:  2008-12-14       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.